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Singlet oxygenNine photo-stable Pt(II) Schiff base complexes [Pt(O^N^N^O)] (Pt1–Pt9) containing tetradentate salicy-
laldimine chelating ligands have been synthesized and characterized as potential photosensitisers for
photodynamic therapy (PDT). The effects of electron-withdrawing versus electron-donating substituents
on their electronic spectral properties are investigated. Pt1–Pt9 show broad absorption bands between
400–600 nm, which makes them useful for green-light photodynamic therapy. The complexes showed
intense phosphorescence with emission maxima at ca. 625 nm. This emission was used to track their cel-
lular localization in cancer cells. Confocal cellular imaging showed that the complexes localized mostly in
the cytoplasm. In the dark, the complexes were non-toxic to A549 human lung cancer cells, but exhibited
high photo-toxicity upon low-dose green light (520 nm, 7.02 J/cm2) irradiation via photo-induced singlet
oxygen generation. Thus, these photoactive Pt(II) complexes have the potential to overcome the problem
of drug resistance and side effects of current clinical Pt(II) drugs, and to act as both theranostic as well as
therapeutic agents.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Photodynamic therapy (PDT) is a non-invasive method used to
treat several types of cancer as well as bacterial or fungal infec-
tions, and various skin diseases [1]. PDT requires the simultaneous
presence of photosensitizers (PSs), oxygen and light [2]. Upon light
activation, the PSs generate reactive oxygen species (ROS) such as
singlet oxygen and hydroxyl radicals [3]. These ROS cause severe
oxidative damage to biomacromolecules such as proteins and
DNA in cancer cells, which triggers cell death [4]. The current clin-
ically approved PSs such as Photofrin, Chlorin e6 and Foscan share
a similar tetrapyrrolic scaffold [5]. As a result, these PSs have sim-
ilar limitations in clinical use, including 1) photo-instability; 2)
high tissue retention times; 3) severe skin sensitivity, and 4) side
effects such as hepatitis [6,7]. Due to the ‘heavy-atom effect’, the
introduction of a heavy metal can significantly enhance the effi-
ciency of PDT. In recent years, metal-based tetrapyrrolic deriva-
tives have been introduced into clinical trials as PDT agents [8,9].
For example, the Pd(II) complex, WST11 shows high absorbance
at 763 nm with the 2–3 deeper light penetration depth thanPhotofrin [10]. However, due to the tetrapyrrolic scaffold, WST11
undergoes rapid photo-degradation which can limit its applica-
tions [11].
To overcome the above limitations, polypyridyl metal com-
plexes have recently attracted significant attention as candidates
for use in PDT with high photo-stability and enhanced aqueous sol-
ubility [12–16]. Among these complexes, TLD-1433, a Ru(II) PS has
entered clinical trials for non-muscle-invasive bladder cancer [17].
On the other hand, Pt(II) complexes such as cisplatin, carbo-
platin, and oxaliplatin are the most widely administered anticancer
drugs in clinic, but their use can be accompanied by side effects
and drug resistance [18]. To overcome these restrictions, over the
last decade, Pt(IV) prodrugs which undergo reduction or light-
induced activation have achieved promising therapeutic effects
[19,20]. The aim of the present work was to investigate novel Pt
(II)-based PSs for PDT which might have fewer side effects and a
different mechanism of action to circumvent resistance to Pt(II)
chemotherapeutics, as well as the disadvantages of the current
organic PDT agents. Recently, Pt(II) complexes have been reported
as PDT agents [21–24], although Pt(II) Schiff base complexes have
been rarely studied, despite their high triplet–triplet annihilation
(TTA) efficiency as a result of the efficient intersystem crossing
(ISC), strong visible light absorption, and high chemical and photo
stability [25–28].r imag-
2 S. Banerjee et al. / Polyhedron xxx (xxxx) xxxHerein, we report the synthesis, photocytotoxicity, and cellular
imaging properties of nine new Pt(II) Schiff base complexes
(Pt1–Pt9). Two of the complexes have been characterized by
X-ray crystal structure determinations. The electronic absorption
and emission properties of the complexes are discussed. The com-
plexes have a broad visible band at ca. 400–600 nm, suitable for
visible light PDT and show strong phosphorescence at ca. 625 nm
with enhancement of phosphorescence in viscous and hydrophobic
solvents for near-IR cellular imaging. The complexes mostly local-
ize in the cytoplasm of cancer cells and exhibit significant photo-
cytotoxicity, while remaining non-toxic in the dark. Overall, these




All solvents were of analytical grade. All buffer components
were of biological grade and used as received. Benzene-1,2-dia-
mine, salicylaldehyde, and 5-methylsalicyclaldehyde, were
obtained from Acros, 4,5-dimethyl-1,2-phenyleneamine, 5-fluoros-
alicyclaldehyde, 1,2-diamino-4,5-difluorobenzene, sulforhodamine
B (SRB), Hoechst 33342, sodium acetate and K2PtCl4, from Sigma-
Aldrich, and MitoTracker deep red FM (MTR) and LysoTracker
green (LTG) from Life Technologies (USA).
2.2. Instruments and methods
2.2.1. X-ray crystallography
Single crystals of Pt5 and Pt9were grown by slow vapour diffu-
sion of diethyl ether into N,N-dimethylformamide solutions of Pt5
or Pt9. A suitable crystal was selected and mounted on a glass fibre
with Fromblin oil and placed on an Xcalibur Gemini diffractometer
with a Ruby CCD area detector. The crystal was kept at 150(2) K
during data collection. Using Olex2 [29], the structure was solved
with the ShelXT [30] structure solution program using Intrinsic
Phasing and refined with the ShelXL [31] refinement package using
Least Squares minimisation. X-ray crystallographic data for Pt5
and Pt9 have been deposited in the CCDC under the accession
numbers 1888366 and 1888367, respectively.
2.2.2. Electrochemistry
Cyclic voltammetry (CV) experiments were carried out using a
CH Instrument model 600D Electrochemical Analyzer/Workstation
(Austin, TX). The electrochemical measurements were performed
on Pt1–Pt9 (1.0 mM) in acetonitrile solutions containing tetra-
butylammonium hexafluorophosphate (0.1 M) as supporting elec-
trolyte. The solutions were degassed under nitrogen and cyclic
voltammograms were scanned from 2.3 V to +2.3 V (three com-
plete scans for each experiment). In a typical electrochemical
experimental set up, the three-electrode system was used: a glassy
carbon electrode as the working electrode, Ag/AgCl in 3.0 M KCl as
the reference electrode, and platinum wire as the counter elec-
trode. CV was performed at a scan rate of 100 mV/s. The excited
state redox potentials were calculated from the ground state redox
potentials and the emission maxima to aid evaluation of the pho-
tosensitization properties of Pt1–Pt9. Excited state reductive
potentials: E([M*]+/[M]2+) = Eox  Ekem, excited state oxidative
potentials: E([M*]+/[M]0) = Ered + Ekem. Ekem = 1240/kem [32].
2.2.3. NMR, UV–Vis, phosphorescence spectroscopy, mass
spectrometry (ESI-MS) and elemental analysis
1H NMR spectra were acquired in 5 mm NMR tubes at 293 K or
310 K on either Bruker DPX 300 (1H = 300.13 MHz) or 400
(1H = 400.13 MHz) spectrometers. 1H NMR chemical shifts werePlease cite this article as: S. Banerjee, M. S. Capper, G. J. Clarkson et al., Dual-acti
ing, Polyhedron, https://doi.org/10.1016/j.poly.2019.04.024internally referenced to DMSO-d6. All data processing was carried
out using MestReC or TOPSPIN version 2.0 (Bruker U.K. Ltd.).
Electronic absorption spectra were recorded on a Cary 300 UV–
Vis spectrophotometer using 1-cm pathlength quartz cuvettes
(3 mL) and a PTP1 Peltier temperature controller. Spectra were
processed using UV Winlab software. Experiments were carried
out at 293 K from 600 to 200 nm.
Phosphorescence emission measurements were obtained on a
JASCO FP-6500 spectrofluorometer. Complexes (10 lM) in acetoni-
trile were diluted from a stock solution in DMSO (1 mM). The com-
plexes were excited at kex = 405 nm, 465 nm and 520 nm in a 1-cm
quartz cuvette at 298 K. Experiments were performed under air or
nitrogen.
Electrospray ionization mass spectra were obtained by prepar-
ing the samples in 50% methanol/50% H2O (v/v), or using NMR
samples, for infusion into the mass spectrometer (Bruker Esquire
2000). The mass spectra were recorded with a scan range of m/z
400–1000 or 800–2000 for positive ions.
CHN analyses were carried out on a CE-440 elemental analyzer
by Warwick Analytical (UK) Ltd.
2.2.4. Determination of singlet oxygen quantum yield
The singlet oxygen production quantum yield was determined
by the N,N-dimethyl-4-nitrosoaniline/imidazole assay based on
the oxidation of imidazole by singlet oxygen by following the reac-
tion of oxidized imidazole with N,N-dimethyl-4-nitrosoaniline, as
reported [33]. The absorbance of the complex was adjusted to ca.
0.1 at the irradiation wavelength. Complexes Pt1–Pt9 (1 mM) in
DMSO were diluted in 4 mL acetonitrile solution containing N,N-
dimethyl-4-nitrosoaniline (20 lM) and imidazole (2 mM), and
irradiated in 1-cm pathlength quartz fluorescence cuvettes.
Bleaching of N,N-dimethyl-4-nitrosoaniline was followed by mon-
itoring of absorbance at 520 nm. Negative control experiments
were run by repetition of the measurements in the absence of imi-
dazole. The absorbance at 420 nm was plotted as a function of irra-
diation time and the quantum yields of singlet oxygen formation
(U sample) were calculated using Rose Bengal as the standard
(Ureference) and the following formula:
Usample ¼ Ureference SsampleSreference
Ireference
Isample
S represents the slope of the absorbance vs. irradiation time, I the
rate of absorption calculated as the overlap of lamp emission spec-





I0 1 10A kð Þ
h i
dk
where I0 represents the light-flux intensity of the lamp and A is the
absorbance of the compound.
2.2.5. Phosphorescence quantum yields and lifetimes
Phosphorescence quantum yields were measured on a Fluo-
rolog spectrofluorometer (Horiba Jobin Yvon) equipped with a
405 nm pulsed diode NanoLED light source. Pt(II) complexes were
diluted from a stock solution in DMSO (1 mM) to achieve an absor-
bance = 0.1 at 405 nm in acetonitrile. The complexes were excited
at kex = 405 nm in a 1-cm quartz cuvette at 298 K. Experiments
were performed in air, and emission spectra were corrected for
the spectral sensitivity of the detection system by standard correc-
tion curves. Quantum yields in aerated acetonitrile were deter-
mined by comparison with the emission of [Ru(bpy)3]Cl2 in
aerated water (U = 0.040). Phosphorescence lifetime measure-
ments using the same equipment and measurement procedure
were continued until 1000 counts of excited state species had beenon platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
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ware by using exponential functions to obtain the phosphores-
cence lifetimes.
2.2.6. Synthesis of the Schiff base ligands and corresponding Pt(II)
complexes
2.2.6.1. General procedure for the synthesis of Schiff base ligands. The
respective salicylaldehyde (2 mol equiv) in ethanol was added
dropwise to a solution of the respective 1,2-phenyldiamines
(1 mol equiv) in ethanol. The mixture was stirred overnight at
room temperature. The yellow precipitate was collected and
washed with cold ethanol.
Ligand 1 was obtained from benzene-1,2-diamine (216.2 mg,
2 mmol) and salicylaldehyde (488.4 mg, 4 mmol). Product:
450.6 mg of yellow powder. Yield: 67%. 1H NMR (300 MHz,
DMSO-d6) d 12.96 (s, 2H), 8.94 (s, 2H), 7.70–7.63 (m, 2H), 7.44
(ddd, J = 15.9, 7.6, 2.7 Hz, 6H), 6.98 (t, J = 7.1 Hz, 4H).
Ligand 2 was obtained from benzene-1,2-diamine (108.1 mg,
1 mmol) and 5-methylsalicyclaldehyde (272.3 mg, 2 mmol) Pro-
duct: 191.6 mg of yellow powder. Yield: 55%. 1H NMR (300 MHz,
DMSO-d6) d 12.66 (s, 2H), 8.86 (s, 2H), 7.46–7.37 (m, 6H), 7.23
(dd, J = 8.4, 1.8 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 2.26 (s, 6H).
Ligand 3 was obtained from benzene-1,2-diamine (108.1 mg,
1 mmol) and 5-fluorosalicyclaldehyde (280.2 mg, 2 mmol). Pro-
duct: 199.5 mg of yellow powder. Yield: 56%. 1H NMR (300 MHz,
DMSO-d6) d 12.61 (s, 2H), 8.91 (s, 2H), 7.53 (dd, J = 9.0, 3.1 Hz,
2H), 7.48–7.36 (m, 4H), 7.28 (td, J = 8.8, 3.2 Hz, 2H), 6.99 (dd,
J = 9.0, 4.5 Hz, 2H).
Ligand 4 was obtained from 4,5-dimethyl-1,2-phenyleneamine
(272.4 mg, 2 mmol) and salicyclaldehyde (488.4 mg, 4 mmol). Pro-
duct: 255 mg of yellow powder. Yield: 35%. 1H NMR (300 MHz,
DMSO-d6) d 13.11 (s, 2H), 8.92 (s, 2H), 7.64 (d, J = 6.9 Hz, 2H),
7.40 (t, J = 7.2 Hz, 2H), 7.28 (s, 2H), 6.97 (t, J = 7.0 Hz, 4H), 2.29 (s,
6H).
Ligand 5 was obtained from 4,5-dimethyl-1,2-phenyleneamine
(136.2 mg, 1 mmol) and 5-methylsalicyclaldehyde (272.3 mg,
2 mmol). Product: 165.6 mg of yellow powder. Yield: 44%. 1H
NMR (300 MHz, DMSO-d6) d 12.81 (s, 2H), 8.85 (s, 2H), 7.43 (s,
2H), 7.26 (s, 2H), 7.22 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H),
2.30 (s, 6H), 2.27 (s, 6H).
Ligand 6 was obtained from 4,5-dimethyl-1,2-phenyleneamine
(136.2 mg, 1 mmol) and 5-fluorosalicyclaldehyde (280.2 mg,
2 mmol). Product: 188.3 mg yellow powder. Yield: 49%. 1H NMR
(300 MHz, DMSO-d6) d 12.74 (s, 2H), 8.91 (s, 2H), 7.52 (dd,
J = 9.0, 3.0 Hz, 2H), 7.31–7.21 (m, 4H), 6.98 (dd, J = 9.0, 4.5 Hz,
2H), 2.30 (s, 6H).
Ligand 7 was obtained from 1,2-diamino-4,5-difluorobenzene
(288.2 mg, 2 mmol) and salicylaldehyde (488.4 mg, 4 mmol). Pro-
duct: 461.6 mg yellow powder. Yield: 62%. 1H NMR (300 MHz,
DMSO-d6) d 12.65 (s, 2H), 8.93 (s, 2H), 7.69 (dd, J = 18.5, 8.5 Hz,
4H), 7.47–7.39 (m, 2H), 6.98 (t, J = 7.5 Hz, 4H).
Ligand 8 was obtained from 1,2-diamino-4,5-difluorobenzene
(144.1 mg, 1 mmol) and 5-methylsalicyclaldehyde (272.2 mg,
2 mmol). Product: 257.5 mg yellow powder. Yield: 67%.1H NMR
(300 MHz, DMSO-d6) d 12.37 (s, 2H), 8.87 (s, 2H), 7.68 (t,
J = 9.9 Hz, 2H), 7.44 (s, 2H), 7.25 (d, J = 8.4 Hz, 2H), 6.87 (d,
J = 8.4 Hz, 2H), 2.27 (s, 6H).
Ligand 9 was obtained from 1,2-diamino-4,5-difluorobenzene
(144.1 mg, 1 mmol) and 5-fluorosalicyclaldehyde (280.2 mg,
2 mmol). Product: 294.2 mg yellow powder. Yield: 75%. 1H NMR
(300 MHz, DMSO-d6) d 12.29 (s, 1H), 8.91 (s, 1H), 7.69 (t,
J = 9.9 Hz, 1H), 7.50 (dd, J = 8.9, 3.0 Hz, 1H), 7.30 (td, J = 8.7,
3.0 Hz, 1H), 7.00 (dd, J = 9.0, 4.4 Hz, 1H).
2.2.6.2. General procedure for the synthesis of platinum(II) com-
plexes. Sodium acetate (49.2 mg, 0.6 mmol) was suspended in aPlease cite this article as: S. Banerjee, M. S. Capper, G. J. Clarkson et al., Dual-acti
ing, Polyhedron, https://doi.org/10.1016/j.poly.2019.04.024solution of ligand L1–L9 (0.3 mmol) in DMF (8 mL). After stirring
for 5 min at room temperature, K2PtCl4 (124.5 mg, 1 mmol) and
DMSO (4 mL) was added. The reaction mixture was heated to
343 K under nitrogen overnight. Upon cooling to room tempera-
ture, diethyl ether (40 mL) was added to afford a red precipitate.
The precipitate was filtered off and washed with water, acetone
and diethyl ether, and dried under vacuum.
Pt1: 70.3 mg of red precipitate. Yield: 46%. 1H NMR (300 MHz,
DMSO-d6) d 9.55 (s, 1H), 8.47 (dd, J = 6.1, 3.4 Hz, 1H), 7.88 (d,
J = 8.1 Hz, 1H), 7.61–7.32 (m, 2H), 7.13 (d, J = 8.5 Hz, 1H), 6.82 (d,
J = 7.8 Hz, 1H). Anal. Calc. for C20H14N2O2Pt: C, 47.15; H, 2.77; N,
5.50. Found: C, 47.33; H, 2.91; N, 5.41. ESI-MS: m/z [M+Na]+
533.4, [2M+Na]+ 1041.0, [3M+Na]+ 1551.2.
Pt2: 56.4 mg of red precipitate. Yield: 35%. 1H NMR (300 MHz,
DMSO-d6) d 9.46 (s, 2H), 8.44 (dd, J = 6.3, 3.3 Hz, 2H), 7.65 (s,
2H), 7.44 (dd, J = 11.7, 5.7 Hz, 4H), 7.04 (d, J = 8.7 Hz, 2H), 2.30 (s,
6H). Anal. Calc. for C22H18N2O2Pt: C, 49.16; H, 3.38; N, 5.21. Found:
C, C, 49.02; H, 3.47; N, 5.35. ESI-MS: m/z [M+Na]+ 561.0, [2M+Na]+
1098.1.
Pt3: 41.0 mg of red precipitate. Yield: 31%. 1H NMR (300 MHz,
DMSO-d6) d 9.57 (s, 1H), 8.42 (dd, J = 6.1, 3.3 Hz, 1H), 7.76–7.32
(m, 3H), 7.13 (dd, J = 9.4, 4.8 Hz, 1H). Anal. Calc. for C20H12F2N2O2-
Pt: C, 44.04; H, 2.22; N, 5.14. Found: C, 43.87; H, 2.26; N, 5.32. ESI-
MS: m/z [M+Na]+ 568.4, [2M+Na]+ 1113.0, [3M+Na]+ 1658.4.
Pt4: 49.8 mg of red precipitate. Yield: 31%. 1H NMR (300 MHz,
DMSO-d6) d 9.43 (s, 2H), 8.23 (s, 2H), 7.84 (d, J = 6.6 Hz, 2H), 7.55
(s, 2H), 7.10 (d, J = 8.5 Hz, 2H), 6.77 (s, 2H), 2.35 (s, 6H). Anal. Calc.
for C22H18N2O2Pt: C, 49.16; H, 3.38; N, 5.21. Found: C, 48.87; H,
3.21; N, 5.33. ESI-MS: m/z [M+Na]+ 561.0, [2M+Na]+ 1098.0, [3M
+Na]+ 1637.1.
Pt5: 59.4 mg of red precipitate. Yield: 35%. 1H NMR (300 MHz,
DMSO-d6) d 9.35 (s, 2H), 8.21 (s, 2H), 7.60 (s, 2H), 7.39 (d,
J = 9.0 Hz, 2H), 7.01 (d, J = 8.7 Hz, 2H), 2.35 (s, 6H), 2.29 (s, 6H).
13C NMR (126 MHz, DMF-d6) d 163.67, 150.08, 143.32, 137.10,
136.95, 134.13, 124.65, 121.96, 121.25, 116.89, 19.36, 19.22. Anal.
Calc. for C24H22N2O2Pt: C, 50.97; H, 3.92; N, 4.95. Found: C, 51.35;
H, 3.78; N, 4.96.ESI-MS: m/z [M+Na]+ 588.1, [2M+Na]+ 1153.1, [3M
+Na]+ 1720.2.
Pt6: 77.4 mg of red precipitate. Yield: 45%. 1H NMR (300 MHz,
DMSO-d6) d 9.33 (s, 1H), 8.07 (s, 1H), 7.55 (d, J = 9.5 Hz, 1H), 7.45
(t, J = 7.7 Hz, 1H), 7.07 (dd, J = 9.3, 4.7 Hz, 1H), 2.28 (s, 3H). 13C
NMR (126 MHz, DMSO-d6) d 161.46, 154.25, 152.41, 150.33,
143.00, 137.66, 124.20, 122.84, 121.13, 118.10, 117.38, 20.04. Anal.
Calc. for C22H16F2N2O2Pt: C, 46.08; H, 2.81; N, 4.89. Found: C,
45.64; H, 2.66; N, 4.86. ESI-MS: m/z [M+Na]+ 595.0, [2M+Na]+
1169.0, [3M+Na]+ 1743.0.
P7: 57.2 mg of red precipitate. Yield: 34%. 1H NMR (300 MHz,
DMSO-d6) d 9.34 (s, 2H), 8.57 (t, J = 9.8 Hz, 2H), 7.75 (d,
J = 7.1 Hz, 2H), 7.57 (t, J = 7.0 Hz, 2H), 7.09 (d, J = 8.6 Hz, 2H), 6.77
(t, J = 7.2 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) d 161.46,
154.25, 152.41, 150.33, 143.00, 137.67, 124.20, 122.85, 121.13,
118.10. Anal. Calc. for C20H12F2N2O2Pt: C, 44.04; H, 2.22; N, 5.14.
Found: C, 43.81; H, 2.05; N,5.02. ESI-MS: m/z [2M+Na]+ 1113.0,
[3M+Na]+ 1659.0.
Pt8: 63.6 mg of red precipitate. Yield: 37%. 1H NMR (300 MHz,
DMSO-d6) d 9.33 (s, 2H), 8.62 (d, J = 10.2 Hz, 2H), 7.55 (s, 2H),
7.43 (d, J = 8.7 Hz, 2H), 7.04 (d, J = 8.7 Hz, 2H), 2.29 (s, 6H). 13C
NMR (126 MHz, DMSO-d6) d 163.48, 152.15, 151.12, 149.5, 147.6,
141.79, 138.08, 134.54, 125.14, 121.74, 121.61, 20.16. Anal. Calc.
for C22H16F2N2O2Pt: C, 46.08; H, 2.81; N, 4.89. Found: C, 45.88; H,
2.69; N, 4.83. ESI-MS: m/z [2M+Na]+ 1171.1, [3M+Na]+ 1744.0.
Pt9: 97.7 mg of red precipitate. Yield: 56%. 1H NMR (300 MHz,
DMSO-d6) d 9.37 (s, 2H), 8.52 (t, J = 9.8 Hz, 2H), 7.51 (d,
J = 8.7 Hz, 4H), 7.13 (s, 2H). 13C NMR (126 MHz, DMF-d6) d
154.49, 152.65, 151.65, 141.84, 128.41, 124.65, 123.04, 120.81,
117.55, 105.29. Anal. Calc. for C20H10F4N2O2Pt: C, 41.32; H, 1.73;on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
4 S. Banerjee et al. / Polyhedron xxx (xxxx) xxxN, 4.82. Found: C, 41.77; H, 2.05; N, 5.49. ESI-MS: m/z [2M+Na]+
1185.0, [3M+Na]+ 1766.9.2.2.7. Cell culture and cell assays
2.2.7.1. Cell culture. The cisplatin-sensitive human lung carcinoma
cell line A549 and cisplatin-resistant human lung carcinoma cell
line A549R were obtained from the European Collection of Cell Cul-
tures (ECACC) and used between passages 5 to 18. Cells were
grown in Roswell Park Memorial Institute medium (RPMI-1640)
supplemented with 10% fetal calf serum and 1% penicillin and
streptomycin. To maintain the resistant phenotype, A549R cells
were incubated with 5 lM cisplatin and cultured in drug-free med-
ium for at least a week before use. The cells were grown as adher-
ent monolayers at 310 K in a 5% CO2 humidified atmosphere and
passaged at ca. 70–80% confluence.2.2.7.2. Dark- and photo-cytotoxicity assays. 5000 A549 cells were
seeded per well in 96-well plates at 310 K in a 5% CO2/95% air incu-
bator (Thermo) for 24 h. Stock solutions of the test compounds
were firstly prepared in 5% DMSO (v/v) and a mixture 0.9% saline
and RPMI-1640 medium (1:1 v/v) following serial dilutions in
RPMI-1640. The drug exposure period was 4 h. After this, super-
natants were removed by suction and each well was washed with
PBS. For light treatment, the cells were then irradiated in phenol-
red-free cell culture medium by 520 nm light (7.02 J cm2). Then
the cells were allowed to recover for a further 44 h in the incubator
at 310 K. For dark-treated cells, after drug exposure, the cells were
incubated in drug-free cell culture medium at 310 K for 44 h.
Finally, the cytotoxicity was determined by sulforhodamine B
(SRB) assay on a GloMax-Multi Microplate Multimode Reader.
IC50 values were determined as duplicates of triplicates in two
independent sets of experiments and their standard deviations
were calculated.2.2.7.3. Cellular localization assays. A549 cells were seeded in a
glass-bottom dish (35 mm dish with 20 mm bottom well (Costar)
at 310 K in a 5% CO2/95% air incubator. The cells were incubated
with Pt1–Pt9 (5 lM) at 310 K for 4 h and further stained with
100 lM MTR and LTR or Hoechst 33,342 Cell imaging was carried
out immediately by confocal microscopy (LSM 710, Carl Zeiss,
Göttingen, Germany) with a 63  oil-immersion objective lens.
Excitation/emission: 1 one-photon 405/562 nm and two-photon
760/562 nm, LTG 488/520 nm, MTR 633/660 nm.Scheme 1. Synthetic route for the Schiff base lig
Please cite this article as: S. Banerjee, M. S. Capper, G. J. Clarkson et al., Dual-acti
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3.1. Synthesis and characterization
To investigate the relationship between the photophysical, pho-
tochemical and photobiological activity of the Pt(II) Schiff base
complexes, we designed and synthesized complexes Pt1–Pt9
(Scheme 1) with either electron-withdrawing or electron-donating
groups at R1 or R2 positions on the backbone phenyl ring. Schiff
base ligands H2L1–H2L9were synthesised by amine-aldehyde con-
densation reactions from disubstituted (–H, –CH3, –F) o-
phenylenediamine and substituted (–H, –CH3, –F) salicylaldehyde
in ethanol at room temperature. All the ligands were characterised
by 1H NMR and mass spectra.
Pt(II) complexes Pt1–Pt9 (Scheme 1) were synthesised by heat-
ing the Schiff base ligand, sodium acetate and K2PtCl4 in DMSO and
DMF (1:1 v/v) at 343 K overnight. All the complexes were charac-
terised by 1H, 13C, COSY NMR, elemental analysis and mass spec-
trometry. The disappearance of the aromatic OH 1H NMR signal
(between 12 and 13 ppm) indicated the coordination of the ligand
to Pt(II). The presence of fluorine at the R1 position strongly influ-
enced the 1H NMR peak splitting patterns. For instance, Pt7
showed a triplet peak at 8.57 but without any proton coupling,
confirmed by the COSY NMR (Fig. S1, SI). Thus the splitting of this
proton signal was due to 19F coupling. Complexes were further
characterized by mass spectral data showing peaks corresponding
to [2M+Na]+ and [3M+Na]+.
3.1.1. X-Ray crystallography
Crystals of Pt5 and Pt9 (Fig. 1, Table S1) suitable for X-ray
diffraction were obtained via diffusion of ethyl ether into DMF
solutions of the complexes. The complexes crystallized in the mon-
oclinic space groups P21/n and P21/c, respectively, with four mole-
cules in the unit cell. They are discrete mononuclear species with a
PtN2O2 core formed by the tetradentate O^N^N^O-donor Schiff
base in a distorted square-planar environment. Pt-O bond dis-
tances are similar in both the complexes (ca. 1.99 Å), slightly
longer than the Pt-N bond distances (ca. 1.96 Å, Table S2). Both
the Pt–O and Pt–N bond distance lies in the range of the previous
literature reports [22,23].
3.1.2. Photochemical and photophysical properties
The convenient structural modifications and facile synthesis of
ligands made it possible to study the structure–activity relation-ands H2L1–9 and Pt(II) complexes Pt1–Pt9.
on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
Fig. 1. Side and top views of the X-ray crystal structures of complexes Pt5 and Pt9 with 50% thermal ellipsoids.
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spectra of Pt1–Pt9 in acetonitrile are shown in Fig. 2. All the solu-
tions of Pt(II) complexes in MeCN were red in colour with similar
absorption spectral features between 200 and 600 nm. The intense
absorption band at around 260 nm is assignable to the Schiff base
ligands, and those near 310 nm are p–p* ligand-based transitions
[34]. The two strong absorption bands between 350 and 400 nm
are assignable to a mixture of metal-to-ligand 1[PtII? p*-(L)] tran-
sitions [34]. The absorption bands in the visible range (420–
600 nm) are metal-to-ligand-charge-transfer (MLCT) bands [25].Fig. 2. The effect of substituents on (a) the UV–Vis spectra of Pt1–Pt9 (10 lM) in ace
Ex = 520 nm.
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electronic absorption spectra. For Pt1, Pt4 and Pt7 with different
substituents at the R1 position, –CH3 induced a hypsochromic
effect (3 nm, in Pt4) and –F induced a bathochromic effect (4 nm,
in Pt7) compared with –H atom (in Pt1). For substitution at the
R2 position, both the –CH3 (15 nm, in Pt2) and –F (23 nm, in Pt3)
groups induced bathochromic effects compared to Pt1. This larger
red-shift of Pt3 (ca 20 nm) compared with Pt7 (4 nm) indicates
that –F substitution at R2 significantly extends the absorption to
longer wavelength. Pt9, where both R1 and R2 are –F, exhibitedtonitrile, and b) normalized emission spectra of Pt1–Pt9 (10 lM) in acetonitrile.
on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
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spectrum tail of Pt9 extended up to 600 nm which is ideal for
near-IR light PDT [35]. Interestingly, Pt4 and Pt5 showed signifi-
cant hypochromic effects and their molar extinction coefficients
are much smaller than those for the other Pt(II) complexes.3.1.3. Oxygen and viscosity sensitivity
Phosphorescence spectra of Pt1–Pt9 were recorded in acetoni-
trile at ambient temperature. Since all the Pt(II) complexes exhibit
strong absorption across the whole visible range, the wavelength
dependence of phosphorescence was investigated. Three excitation
wavelengths were selected: 405 nm, 465 nm and 520 nm. As
shown in Fig. 3, Pt1–Pt9 (10 lM) all exhibited red phosphores-
cence between 604 and 644 nm. The highest emission intensity
was obtained with excitation at 520 nm.
Similar to the UV–Vis absorption spectra, substitution at the R1
or R2 position also influenced the emission spectra (Fig. 3). Pt1, Pt4
and Pt7 displayed the most blue-shifted emission maximum at
604, 607 and 609 nm, respectively, compared with R2-substituted
complexes. Substitution with either –CH3 or –F group at R2 signif-
icantly shifted the emission maximum to longer wavelength (e.g.
Pt1 604 nm, Pt2 625 nm, Pt3 633 nm) while the –F substituent
showed a more effective red-shift than –CH3. Taking the emission
and the UV–Vis data into consideration, it is apparent that a sub-
stituent at the R2 position has a stronger effect on the emission
and absorbance properties of Pt(II) Schiff base complexes than
the R1 position.
The emission spectra were recorded under N2 in acetonitrile to
investigate the effect of oxygen on the emission. As shown in
Fig. 3a and b, the emission intensity of all the Pt(II) complexes
under a nitrogen environment increased significantly compared
to the intensity measured under air. Pt2was the most oxygen-sen-
sitive complex with a 32 phosphorescence enhancement under
nitrogen (Fig. 3c). Pt1 showed the smallest emission enhancementFig. 3. (a) Emission spectra of Pt2 (10 lM) in acetonitrile in air. (b) Emission spectra of P
air and under nitrogen. (d) Concentration dependent phosphorescence intensity of Pt1
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emission in air. The phosphorescence of the complexes can be used
to track the complexes inside cells by cellular imaging. Moreover,
upon introducing functional groups, the phosphorescence intensity
of Pt7 showed a better linear relationship with increasing concen-
tration than Pt1 (Fig. 3d). Thus the functional groups may intro-
duce steric hindrance which might obstruct p–p stacking
between the planar Pt(II) complexes.
3.1.4. Effect of solvent polarity and viscosity
The influence of polarity and viscosity on the emission of the
complexes Pt1–9 is important for the possible use of these com-
plexes as cellular imaging or PDT agents since the intracellular
microenvironment is complicated with areas of varied polarity
and viscosity [36]. As shown in Fig. 4 b, solvent polarity has only
a little effect on the emission intensities. However, the viscosity
of the solvent has a strong influence. The phosphorescence inten-
sity was much higher in viscous solvents like glycerol compared
to the other low viscosity solvents as depicted in Fig. 4a,b. Further-
more, at different percentages of glycerol/water the phosphores-
cence intensity was enhanced significantly with increased
percentage of glycerol. Complex Pt7, in particular displayed the
highest intensity enhancement in the presence of glycerol com-
pared with all other Pt(II) complexes. The phosphorescence life-
time of Pt7 in acetonitrile and glycerol indicated (Fig. 4a) that
Pt7 has a more than 40x longer excited-state lifetime time in glyc-
erol (3277 ns) than in acetonitrile (80.7 ns). These results indicate
that high viscosity and hydrophobic environments enhance the
phosphorescence intensity of these Pt(II) Schiff base complexes.
3.1.5. Cyclic voltammetry
Cyclic voltammograms of Pt1–Pt9 were recorded in degassed
DMF (1 mM) with 100 mM tetrabutylammonium hexafluorophos-
phate (TBAP) as supporting electrolyte. All potentials are refer-t2 (10 lM) under nitrogen. (c) Comparison of emission intensity of Pt1–9 (10 lM) in
(black) and Pt7 (red) in air-saturated acetonitrile. (Colour online.)
on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
Fig. 4. (a) Excited state lifetime measurement for Pt7 in air-saturated acetonitrile and glycerol. (b) Emission intensity of Pt1–Pt9 (3 lM) in solvents of varying polarity and
viscosity.
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case, there is one irreversible anodic peak with Epa at 0.424–
0.687 V and one irreversible cathodic peak with Epc at 1.733 to
2.019 V (Fig. S2). The anodic and cathodic peaks are attributed
to the oxidation and reduction of Schiff base ligands, respectively
[25]. Introduction of the –CH3 group reduced the oxidation poten-
tial, while –F increased both the oxidation and reduction potentials
in all of the complexes. The excited-state redox potentials of the
complexes were determined in order to assess the photosensitiza-
tion properties of the complexes (Table 1). Upon excitation by
green light, these Pt(II) Schiff base complexes became more reduc-
tive rather than oxidative.
3.1.6. Singlet oxygen generation
The highly oxygen-sensitive emission of the Pt(II) complexes
indicates that the complexes probably interact with 3O2 in their
excited states and may generate singlet oxygen (1O2) upon
photo-excitation. Thus the singlet oxygen quantum yields of Pt1–
Pt9 were determined in acetonitrile using both indirect and direct
methods. The indirect method tracks the photo bleaching of N,N-
dimethyl-4-nitrosoaniline (RNO) induced by imidazole and singlet
oxygen over time. The direct method records the laser power
dependence of near infrared singlet oxygen phosphorescence spec-
tra, with Rose Bengal as a reference photosensitizer.
Singlet oxygen phosphorescence spectra with emission maxi-
mum at 1270 nm were observed for all the Pt(II) complexes
(Fig. 5a,b). Pt3, Pt6 and Pt7 with –F substitution showed relatively
higher singlet oxygen quantum yields of 46%, 43% and 42%, respec-
tively. Previous studies also showed that the presence of a fluorine
substituent increases the antitumor effects with enhanced singlet
oxygen generation [37,38]. These Pt(II) complexes exhibitedTable 1
Electrochemical properties of Pt1–Pt9 and their calculated excited-state redox
potentials.
Complexes Ground State Excited State
Epa/V Epc/V *E(M/[M]+)/V *E(M/[M])/V
Pt1 0.581 1.946 1.471 0.106
Pt2 0.456 1.982 1.528 0.002
Pt3 0.525 1.827 1.433 0.131
Pt4 0.517 1.997 1.525 0.045
Pt5 0.424 2.019 1.556 0.038
Pt6 0.612 1.857 1.337 0.092
Pt7 0.648 1.873 1.388 0.163
Pt8 0.517 1.911 1.467 0.073
Pt9 0.687 1.733 1.238 0.192
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photo-irradiation, making them suitable as PDT agents.
3.1.7. Cell imaging and cellular localization
Based on the unique phosphorescence property of the com-
plexes, confocal microscopy imaging of Pt1–Pt9 treated living
A549 lung cancer cells under 520 nm excitation was carried out
to track the complexes inside cancer cells. As shown in Fig. 6, under
520 nm excitation, Pt1–Pt3 showed much stronger intracellular
phosphorescence than the other Pt(II) complexes, especially Pt7–
Pt9 whose intracellular phosphorescence was too weak to detect.
From the cell imaging data, it was evident that the Pt(II) complexes
have similar intracellular localization, mostly in the cytoplasm.
Subsequently, to confirmwhether these Pt(II) complexes can target
specific organelles in the cytoplasm, Pt1 was selected for co-stain-
ing with commercial organelle dyes due to its strongest intracellu-
lar phosphorescence intensity. A549 lung cancer cells were firstly
incubated with Pt1 (5 lM, 4 h) and then with specific organelle
dyes (30 min) in the dark, and finally imaged with a confocal
microscope. As shown in Fig. 7, the red signal of Pt1 overlayed with
both the fluorescence signal of Mitotracker green (mitochondrion-
staining dye) and of Lysotracker green (lysosome-imaging dye). No
overlay of luminescence was observed with the nucleus-staining
dye Hoechst 33342. All these data indicate that these Pt(II) com-
plexes target cell mitochondria and lysosomes rather than the cell
nucleus. Clinically approved Pt(II) drugs such as cisplatin and car-
boplatin are known to target the cell nucleus and cross-link
nuclear DNA [39]. Resistance to these Pt drugs occurs due to the
repair of such platinum-DNA cross links by a nucleotide excision
repair mechanism [40]. Hence these mitochondrion- and lyso-
some-targeting complexes could provide a novel mechanism of
anticancer activity to overcome Pt-drug resistance.
3.1.8. Photocytotoxicity
After confirming the intracellular internalization and specific
distribution of complexes Pt1–9 in A549 cancer cells, we explored
the anticancer activity of these complexes, particularly as PDT
agents considering their excellent ability to generate 1O2. The anti-
cancer activity of these complexes was studied both in the dark
and upon light irradiation. As shown in Table 2, all the Pt(II) com-
plexes were non-toxic in A549 cancer cells in the dark up to 20 mM
concentration, the cell survival percentages were all >80% after 4 h
drug exposure followed by 44 h recovery. However, upon irradia-
tion with a low dose of 520 nm green light (7.02 J/cm2), significant
photo-toxicity was observed, with several giving nanomolar IC50on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
Fig. 5. a) Near-infrared singlet oxygen signal generated by Pt1–Pt9 after irradiation with 520 nm light in acetonitrile. b) Singlet oxygen generation quantum yields measured
from the absorption attenuation (DA = A0 – At) of RNO under 520 nm light exposure in acetonitrile. The slope corresponds to the absolute amount of generated 1O2.
Fig. 6. Live A549 lung cancer cell imaging with the Pt(II) Schiff base complexes. Excitation wavelength: 520 nm. Emission filter: 600 ± 40 nm.
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Fig. 7. Intracellular localization of Pt1 in A549 lung cancer cells. A549 cells were firstly incubated with Pt1 (5 lM, 4 h), and then with commercial dyes for another 30 min.
Scale bar = 50 lm. Excitation wavelengths: 520 nm for Pt1, 488 nm for Mitotracker and Lysotracker, 405 nm for Hoechst 33342. Emission filter: 600 ± 20 nm for Pt(II)
complexes, 520 ± 20 nm for Mitotracker and Lysotracker, 460 ± 20 nm for Hoechst 33342.
Table 2
Dark- and photo-toxicity of Pt1–Pt9 towards A549 and cisplatin-resistant A549R lung cancer cells (IC50/lM).
Cell line A549 A549R
Compound Darka Lighta PI Darka Lighta PI
Pt1a >20 0.20 ± 0.015 >100 >20 0.30 ± 0.010 >66
Pt2a >20 0.13 ± 0.007 >159 >20 0.12 ± 0.011 >166
Pt3a >20 0.21 ± 0.025 >98 >20 0.35 ± 0.023 >57
Pt4a >20 0.15 ± 0.010 >134 >20 0.23 ± 0.015 >87
Pt5a >10 1.50 ± 0.021 >7 n.d. n.d. n.d.
Pt6a >10 8.05 ± 0.69 >1 n.d. n.d. n.d.
Pt7a >20 0.37 ± 0.025 >55 n.d. n.d. n.d.
Pt8a >10 >10 n.a. n.d. n.d. n.d.
Pt9a >10 >10 n.a. n.d. n.d. n.d.
Cisplatina 55.6 ± 6.3 54.7 ± 4.4 n.a. >200 >200 n.d.
Cisplatinb 4.6 ± 0.5 4.7 ± 0.3 n.a. 32.4 ± 3.5 34.0 ± 2.9 n.d.
5-ALA >200 >200 n.a. >200 >200 n.d.
a The drug exposure time was 4 h. The cells were washed, replaced with fresh cell culture medium and then received dark or light (520 nm, 7.02 J/cm2) treatment followed
by 44 h recovery.
b The drug exposure time was 48 h. n.d.: not detected. n.a.: not available.
S. Banerjee et al. / Polyhedron xxx (xxxx) xxx 9values. Pt2–Pt5 exhibited much better phototoxicity than Pt1
(which contained no substituents).
4. Conclusions
A series of platinum(II) Schiff Base salicylaldimine complexes
(Pt1–Pt9) was synthesized with hydrogen, fluorine and methyl
substituents on various positions on the phenyl rings of the back-
bone. The effect of electron withdrawing and donating substituents
on the absorption and emission properties was investigated. ThesePlease cite this article as: S. Banerjee, M. S. Capper, G. J. Clarkson et al., Dual-acti
ing, Polyhedron, https://doi.org/10.1016/j.poly.2019.04.024Pt(II) complexes show intense visible light absorption between 400
and 600 nm due to metal-to-ligand-charge-transfer (MLCT). Inter-
estingly, the complexes showed viscosity and polarity-dependent
strong emission upon green light excitation. Pt1–Pt9 showed
excellent photo-stability under continuous light irradiation and
generated singlet oxygen with a quantum yield of ca. 50%.
In the dark, all the complexes were non-toxic to A549 lung can-
cer cells. However, strong photo-toxicity was observed after excita-
tion with low-dose green light (520 nm, 7.02 J cm2). Cell imaging
indicated that the complexes mostly localized in the cytoplasm,on platinum(II) Schiff base complexes: Photocytotoxicity and cellular imag-
10 S. Banerjee et al. / Polyhedron xxx (xxxx) xxxtargeting mitochondria and lysosomes efficiently. In general, this
new series of green-light-activated Pt(II) Schiff base complexes
has potential as photosensitizers for photodynamic therapy with
mitochondria- and lysosome-targeting ability. The Pt(II) complexes
show anticancer activity only upon light irradiation while remain-
ing dormant in the dark. All these properties indicate that the
complexes have the potential to overcome the problems of drug
resistance and side effects of current clinical Pt(II) drugs.
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